AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.
• € 10m additional capital raised
• Supervisory Board appoints Oliver Siegel as Chief Executive Officer
• Prof. Dr. Christoph Huber elected to Supervisory Board